feedback

Course Director

Michael Wang, MD
Michael Wang, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Michael J. Keating
Michael J. Keating, MB, BS

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2018-Oct-12
Expiration Date:2019-Oct-11
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity, experts in lymphoma discuss how to effectively select validated Bruton's tyrosine kinase (BTK) inhibitors for various non-Hodgkin lymphoma types and how to safely integrate BTK inhibitors in to the current treatment paradigm while considering appropriate patient-specific factors and prior treatment history. The panel addresses other challenging clinical conundrums by offering their informed views on the key science on BTK inhibitor therapy across B-cell malignancies as well as guidance on real-world application of the most recent, relevant evidence to best bridge the divide between clinical research and daily practice.

Upon completion of this activity, participants should be better able to:
  • Review the latest evidence on safety and efficacy of BTK inhibitors in the management of B-cell non-Hodgkin lymphoma (NHL)
  • Incorporate BTK inhibitors into treatment regimens for newly diagnosed or previously treated B-cell NHL, including in the context of clinical trials
  • Apply effective strategies to manage dosing and treatment-related adverse events in patients with B-cell NHL receiving BTK inhibitors

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with B-cell non-Hodgkin lymphoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 12, 2018 - October 11, 2019
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Michael Wang, MD
Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael Wang, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Janssen Pharmaceuticals, Inc.; and MoreHealth.
Grant/Research Support from Acerta Pharma; AstraZeneca; BeiGene; BioInvent; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Juno Therapeutics; Karus Therapeutics; Kite Pharma, Inc.; Novartis Pharmaceuticals Corporation; Oncternal Therapeutics; and Pharmacyclics LLC.
Michael Wang, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: BTK inhibitors in a range of B-cell NHLs.

Faculty

Michael J. Keating, MB, BS
Clinical Professor, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael J. Keating, MB, BS, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation and F. Hoffmann-La Roche Ltd.
Advisory Board for Celgene Corporation and F. Hoffmann-La Roche Ltd.
Michael J. Keating, MB, BS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: BTK inhibitors in a range of B-cell NHLs.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.